KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Assets (2016 - 2026)

AbbVie has reported Assets over the past 14 years, most recently at $134.0 billion for Q4 2025.

  • Quarterly Assets fell 0.89% to $134.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $134.0 billion through Dec 2025, down 0.89% year-over-year, with the annual reading at $134.0 billion for FY2025, 0.89% down from the prior year.
  • Assets was $134.0 billion for Q4 2025 at AbbVie, roughly flat from $133.9 billion in the prior quarter.
  • Over five years, Assets peaked at $150.5 billion in Q1 2021 and troughed at $133.9 billion in Q3 2025.
  • The 5-year median for Assets is $140.1 billion (2022), against an average of $140.6 billion.
  • Year-over-year, Assets skyrocketed 65.02% in 2021 and then dropped 8.54% in 2025.
  • A 5-year view of Assets shows it stood at $146.5 billion in 2021, then fell by 5.27% to $138.8 billion in 2022, then decreased by 2.95% to $134.7 billion in 2023, then rose by 0.33% to $135.2 billion in 2024, then dropped by 0.89% to $134.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Assets are $134.0 billion (Q4 2025), $133.9 billion (Q3 2025), and $137.2 billion (Q2 2025).